6533b822fe1ef96bd127d6e6
RESEARCH PRODUCT
Insulin-like growth factor 1 and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy
Emilio NardiGiuseppe AndronicoM.t. ManganoGiovanni CerasolaG. PiazzaGiuseppe Mulèsubject
AdultMalemedicine.medical_specialtyErythrocytesVascular smooth muscleLithium (medication)Heart diseasePhysiologymedicine.medical_treatmentEssential hypertensionLeft ventricular hypertrophyAntiportersMuscle hypertrophyInsulin-like growth factorReference ValuesInternal medicineInternal MedicineHumansMedicineInsulin-Like Growth Factor Ibusiness.industryGrowth factorMiddle Agedmedicine.diseaseEndocrinologyHypertensionFemaleHypertrophy Left VentricularCardiology and Cardiovascular Medicinebusinessmedicine.drugdescription
The aim of this work was to study the insulin-like growth factor 1 (IGF1), a substance able to promote cell proliferation in vascular smooth muscle, in patients with mild-to-moderate hypertension and to analyse its relationship to sodium-lithium countertransport, a genetic marker of hypertension that is related to cardiovascular complications.We studied 32 hypertensive subjects, some with left ventricular hypertrophy, and 14 healthy subjects. Fasting plasma IGF1 was measured by means of a radioimmunoassay after octadecylsilica chromatography and Na(+)-Li+ countertransport was determined by the method of Canessa.Hypertensive patients had higher values of both IGF1 and Na(+)-Li+ countertransport. We found a positive correlation, irrespective of age, between IGF1 and Na(+)-Li+ countertransport. The patients with left ventricular hypertrophy had significantly higher plasma IGF1 levels than those without left ventricular hypertrophy.Our results confirm a possible role for IGF1 in the cardiovascular complications of hypertension and emphasize its relationship to genetically determined factors.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1993-10-01 |